Leaflet THROMBOREDUCTIN 0.5mg capsules

Indicated for: essential thrombocythemia

Route of administration: oral

Substance: anagrelide (anticoagulant)

ATC: L01XX35 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)

Precautions:

Dose adjustment in renal impairment

Dose adjustment may be needed in kidney disease.

Major drug interactions

This medicine may have important interactions with other medicines.

Additional monitoring

This medicine is subject to additional monitoring.

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.

Bleeding risk

This medicine may increase the risk of bleeding.

Anagrelide is a medication used for the treatment of essential thrombocythemia, a hematological condition characterized by an excessive number of platelets in the blood. This condition can increase the risk of blood clot formation, leading to complications such as strokes or heart attacks. Anagrelide works by inhibiting the maturation of megakaryocytes, the precursors of platelets, thereby reducing the platelet count in the blood.

Anagrelide is administered orally, usually two to four times daily, with the dosage adjusted based on the patient's response and platelet levels.

Common side effects include headaches, dizziness, nausea, diarrhea, and palpitations. In rare cases, severe adverse reactions such as heart failure or liver function impairment may occur.

Patients taking anagrelide should undergo regular monitoring for platelet counts and signs of adverse reactions. Additionally, the medication may interact with other anticoagulant or antiplatelet therapies, requiring caution. Anagrelide is an effective option for managing essential thrombocythemia, helping to reduce the risk of thrombotic complications.

General data about THROMBOREDUCTIN 0.5mg

Substance: anagrelide
Date of latest medicines list: 01-06-2026
Product code: W61708002
Concentration: 0.5mg
Pharmaceutical form: capsules
Quantity: 100
Product type: Original
Price: 589.60 RON
Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer: AOP ORPHAN PHARMACEUTICALS AG - AUSTRIA
Holder: AOP ORPHAN PHARMACEUTICALS AG - AUSTRIA
Number: 7585/2015/02
Shelf life: 3 years

Pharmaceutical forms available for anagrelide

Concentrations available for anagrelide

0.5mg
0.75mg
1mg

Compensation lists for THROMBOREDUCTIN 0.5mg AOP Orphan Pharmaceuticals

G10 (C1) - Leukemias, lymphomas and bone marrow aplasia, tumors

Price

Copayment

Patient

589.60 RON

0.00 RON

GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)